Rola eozynofila w przewlekłej pokrzywce autoimmunologicznej

##plugins.themes.bootstrap3.article.main##

Agnieszka Fluder
Anna Wolańczyk-Mędrala

Abstrakt

Praca przedstawia zagadnienia dotyczące udziału eozynofilów w patogenezie przewlekłej pokrzywki autoimmunologicznej. Autorzy przedstawili dane na temat migracji tych komórek do miejsc zapalnych w odpowiedzi na szereg bodźców chemotaktycznych oraz uwalnianie wielu mediatorów prozapalnych. Opisano także nowo odkrytą możliwość bezpośredniej aktywacji tych komórek przez autoprzeciwciała anty-FcεRII, a także aktualne i rozważane do zastosowania w przyszłości możliwości terapeutyczne w przewlekłej pokrzywce autoimmunologicznej.


 

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.themes.bootstrap3.article.details##

Jak cytować
Fluder , A., & Wolańczyk-Mędrala , A. (2008). Rola eozynofila w przewlekłej pokrzywce autoimmunologicznej. Alergoprofil, 4(1), 23-26. Pobrano z https://journalsmededu.pl/index.php/alergoprofil/article/view/45
Dział
Artykuł

Bibliografia

1. Rosińska A., Łopińska P., Karpisiewicz M. et al.: Prawdopodobne przyczyny pokrzywki przewlekłej u chorych hospitalizowanych w Klinice Dermatologii Akademii Medycznej w Poznaniu w latach 1997-2003. PDiA 2004, 21: 128-135.
2. Bernstein J.A.: Chronic urticaria: an evolving story. Isr. Med. Assoc. J. 2005, 7: 774-777.
3. Grattan C.E., Wallington T.B., Warin R.P. et al: A serological mediator in chronic idiopathic urticaria - a clinical, immunological and histological evaluation. Br. J. Dermatol. 1986, 114: 583-590.
4. Caproni M., Volpi W., Macchia D. et al.: Infiltrating cells and related cytokines in lesional skin of patients with chronic idiopathic urticaria and positive autologous serum skin test. Exp. Dermatol. 2003, 12: 621-628.
5. Hide M., Francis D.M., Grattan C.E.H. et al.: Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N. Engl. J. Med. 1993, 328: 1599-1604.
6. Brunetti L., Francavilla R., Miniello V.L. et al.: High prevalence of autoimmune urticaria in children with chronic urticaria. J. Allergy Clin. Immunol. 2004, 114: 922-927.
7. Fusari A., Colangelo C., Bonifazi F. et al.: The autologous serum skin test in the follow-up of patients with chronic urticaria. Allergy 2005, 60: 256-258.
8. Erbagci Z.: Multiple NSAID intolerance in chronic idiopathic urticaria is correlated with delayed, pronounced and prolonged autoreactivity. J. Dermatol. 2004, 31: 376-382.
9. Kaplan A.P., Joseph K., Shibayama Y. et al.: Bradykinin formation: plasma and tissue pathways and cellular interactions. W: Inflammation: basic principles and clinical correlates. Gallin J., Snyderman R. (red.). Wyd. 3, Lippincott, Williams and Wilkins, Philadelphia 1999: 331-347.
10. Ward P.A., Hill J.H.: C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils. J. Immunol. 1970, 104: 535-543.
11. Fiebiger E., Hammerschmid F., Stingl G. et al.: Anti-FceRIα autoantibodies in autoimmune-mediated disorders. Identification of a structure–function relationship. J. Clin. Invest. 1998, 101: 243-251.
12. Tam S.W., Demissie S., Thomas D. et al.: A bispecific antibody against human IgE and human FcgammaRII that inhibits antigen-induced histamine release by human mast cells and basophils. Allergy 2004, 59: 772-780.
13. Horn M.P., Pachlopnik J.M., Vogel M. et al.: Conditional autoimmunity mediated by human natural anti-Fc(epsilon)RIalpha autoantibodies? FASEB J. 2001, 15: 2268-2274.
14. Asero R., Lorini M., Chong S.U. et al.: Assessment of histamine-releasing activity of sera from patients with chronic urticaria showing positive autologous skin test on human basophils and mast cells. Clin. Exp. Allergy 2004, 34: 1111-1114.
15. Giembycz M.A., Lindsay M.A.: Pharmacology of the eosinophil. Pharm. Rev. 1999, 51: 213-340.
16. Tavernier J. H., Plaetinck G., Guisez Y. et al.: The role of interleukin-5 in the production and function of eosinophils. W: Hematopoietic Cell Growth Factors and Their Receptors. Whetton and Gordon (red.). Plenum Press, New York 1996: 321-361.
17. Sur S., Lam J., Bouchard P.: Immunomodulatory effects of IL12 on allergic lung inflammation depend on timing of doses. J. Immunol. 1996, 157: 4173-4180.
18. Forssmann U., Uguccioni M., Loetscher P. et al: Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3 and acts like eotaxin on human eosinophil and basophil leukocytes. J. Exp. Med.1997, 185: 2171-2176.
19. Ying S., Robinson D.S., Meng Q. et al.: C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemes (monocyte chemoattractant protein-3 and RANTES). J. Immunol.1999, 163: 3976-3984.
20. Keane-Myers A., Wysocka M., Trinchieri G. et al.: Resistance to antigen-induced airway hyperresponsiveness requires endogenous production of IL-12. J. Immunol. 1998, 161: 919-926.
21. Trinchieri G.: Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann. Rev. Immunol. 1995, 13: 251-276.
22. Jonkers R.E., van der Zee J.S.: Anti-IgE and other new immunomodulation-based therapies for allergic asthma. Neth. J. Med. 2005, 63: 121-128.
23. Caproni M., Volpi W., Macchia D. et al.: Infiltrating cells and related cytokines in lesional skin of patients with chronic idiopathic urticaria and positive autologous serum skin test. Exp. Dermatol. 2003, 12, 621-628.
24. Sabroe R.A., Poon E., Orchard G.E. et al.: Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J. Allergy Clin. Immunol. 1999, 103: 484-493.
25. O’Donnel B.F., Barr R.M., Black A.K. et al.: Intravenous immunoglobulin in autoimmune chronic urticaria. Br. J. Dermatol. 1998, 138: 101-106.
26. Grattan C.E., Francis D.M., Slater N.G.: Plasmapheresis for severe, unremitting, chronic urticaria. Lancet 1992, 2(8801): 1078-1080.
27. Grattan C.E., O’Donnell B.F., Francis D.M. et al.: Randomized double-blind study of cyclosporin in chronic ’idiopathic’ urticaria. Br. J. Dermatol. 2000, 143: 365-372.
28. Płusa T.: Strategia leczenia chorób alergicznych. PDiA 2003, 20: 66-72.
29. Leckie M.J., Ten Brinke A., Khan J. et al.: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356(9248): 2144-2148.
30. Dent G., Hadjicharalambous C., Yoshikawa T. et al.: Contribution of eotaxin-1 to eosinophil chemotactic activity of moderate and severe asthmatic sputum. Am. J. Respir. Crit. Care Med. 2004, 169: 1110-1117.